201 related articles for article (PubMed ID: 18414463)
1. A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet.
Falchetti A; Cilotti A; Vaggelli L; Masi L; Amedei A; Cioppi F; Tonelli F; Brandi ML
Nat Clin Pract Endocrinol Metab; 2008 Jun; 4(6):351-7. PubMed ID: 18414463
[TBL] [Abstract][Full Text] [Related]
2. Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1.
Del Prete M; Marotta V; Ramundo V; Marciello F; Di Sarno A; Esposito R; Carratù AC; De Luca Di Roseto C; Di Somma C; Colao A; Faggiano A
Minerva Endocrinol; 2013 Dec; 38(4):389-94. PubMed ID: 24285106
[TBL] [Abstract][Full Text] [Related]
3. MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly.
Filopanti M; Verga U; Ermetici F; Olgiati L; Eller-Vainicher C; Corbetta S; Persani L; Beck-Peccoz P; Spada A
Eur J Endocrinol; 2012 Aug; 167(2):157-64. PubMed ID: 22577108
[TBL] [Abstract][Full Text] [Related]
4. Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1).
Giusti F; Cianferotti L; Gronchi G; Cioppi F; Masi L; Faggiano A; Colao A; Ferolla P; Brandi ML
Endocrine; 2016 Jun; 52(3):495-506. PubMed ID: 26224587
[TBL] [Abstract][Full Text] [Related]
5. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.
Faggiano A; Tavares LB; Tauchmanova L; Milone F; Mansueto G; Ramundo V; De Caro ML; Lombardi G; De Rosa G; Colao A
Clin Endocrinol (Oxf); 2008 Nov; 69(5):756-62. PubMed ID: 18485119
[TBL] [Abstract][Full Text] [Related]
6. Cinacalcet for the treatment of primary hyperparathyroidism.
Sajid-Crockett S; Singer FR; Hershman JM
Metabolism; 2008 Apr; 57(4):517-21. PubMed ID: 18328354
[TBL] [Abstract][Full Text] [Related]
7. Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy.
Iglesias P; Ais G; González A; Tajada P; García Arévalo C; Fernández Pardo E; Díez JJ
Am J Med Sci; 2008 Feb; 335(2):111-4. PubMed ID: 18277118
[TBL] [Abstract][Full Text] [Related]
8. Multiple endocrine neoplasia type 1 in end-stage renal failure.
Suzuki H; Katoh T; Sakuma Y; Takahashi M; Asahi K; Hashimoto S; Kosugi S; Suzuki S; Takenoshita S; Watanabe T
Clin Exp Nephrol; 2004 Dec; 8(4):380-3. PubMed ID: 15619041
[TBL] [Abstract][Full Text] [Related]
9. Parathyroid carcinoma occurred in two glands in multiple endocrine neoplasia 1: a report on a rare case.
Omi Y; Horiuchi K; Haniu K; Tokura M; Nagai E; Isozaki O; Nagashima Y; Okamoto T
Endocr J; 2018 Feb; 65(2):245-252. PubMed ID: 29225207
[TBL] [Abstract][Full Text] [Related]
10. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
Dong BJ
Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
[TBL] [Abstract][Full Text] [Related]
11. Cinacalcet (Sensipar) provides no measurable clinical benefits for patients with primary hyperparathyroidism and may accelerate bone loss with prolonged use.
Norman J; Lopez J; Politz D
Ann Surg Oncol; 2012 May; 19(5):1466-71. PubMed ID: 21922336
[TBL] [Abstract][Full Text] [Related]
12. Is total parathyroidectomy the treatment of choice for hyperparathyroidism in multiple endocrine neoplasia type 1?
Tonelli F; Marcucci T; Fratini G; Tommasi MS; Falchetti A; Brandi ML
Ann Surg; 2007 Dec; 246(6):1075-82. PubMed ID: 18043113
[TBL] [Abstract][Full Text] [Related]
13. Elevated parathyroid hormone levels after parathyroidectomy for primary hyperparathyroidism.
Mizrachi A; Gilat H; Bachar G; Feinmesser R; Shpitzer T
Head Neck; 2009 Nov; 31(11):1456-60. PubMed ID: 19405085
[TBL] [Abstract][Full Text] [Related]
14. [Primary hyperparathyroidism].
Ventz M; Quinkler M
Dtsch Med Wochenschr; 2010 Oct; 135(41):2024-30. PubMed ID: 20925010
[TBL] [Abstract][Full Text] [Related]
15. Hypercalcemia of primary hyperparathyroidism was treated by cinacalcet in a patient with liver cirrhosis.
Akinci B; Comlekci A; Tankurt E
Exp Clin Endocrinol Diabetes; 2009 Mar; 117(3):142-5. PubMed ID: 18561096
[TBL] [Abstract][Full Text] [Related]
16. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism.
Kruse AE; Eisenberger U; Frey FJ; Mohaupt MG
Nephrol Dial Transplant; 2005 Jul; 20(7):1311-4. PubMed ID: 15941846
[TBL] [Abstract][Full Text] [Related]
17. Primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1: comparison with sporadic parathyroid adenomas.
Katai M; Sakurai A; Ikeo Y; Hashizume K
Horm Metab Res; 2001 Aug; 33(8):499-503. PubMed ID: 11544565
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment of secondary hyperparathyroidism with the calcimimetic cinacalcet HCl.
Moe SM; Cunningham J; Bommer J; Adler S; Rosansky SJ; Urena-Torres P; Albizem MB; Guo MD; Zani VJ; Goodman WG; Sprague SM
Nephrol Dial Transplant; 2005 Oct; 20(10):2186-93. PubMed ID: 16030053
[TBL] [Abstract][Full Text] [Related]
19. [Cinacalcet--a new drug for the treatment of secondary hyperparathyroidism in patients with uraemia, parathyroid cancer or primary hyperparathyroidism].
Vestergaard P; Nielsen LR; Mosekilde L
Ugeskr Laeger; 2006 Jan; 168(1):29-32. PubMed ID: 16393559
[TBL] [Abstract][Full Text] [Related]
20. Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism.
Imanishi Y; Kawata T; Kenko T; Wada M; Nagano N; Miki T; Arnold A; Inaba M
Calcif Tissue Int; 2011 Jul; 89(1):29-35. PubMed ID: 21541686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
